AURA Stock Analysis: Buy, Sell, or Hold?
AURA - Aura Biosciences, Inc. Common Stock
$7.09
-0.65 (-8.40%)
▼
5d:
+1.29%
30d:
+3.05%
90d:
+8.41%
BUY
MODERATE Confidence
Analysis Updated: Jul 6, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When AURA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: AURA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: AURA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: AURA is currently trading at $7.09, which is considered slightly high relative to its 30-day fair value range of $6.38 to $7.21.
Technical Outlook: Technically, AURA is in a uptrend. Immediate support is located at $6.41, while resistance sits at $7.87. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: AURA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.80 (+165.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, AURA is in a uptrend. Immediate support is located at $6.41, while resistance sits at $7.87. Short-term momentum is weak, with the stock down 8.4% recently.
Market Sentiment: AURA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $18.80 (+165.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$6.38 -
$7.21
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.7%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.4%)
- BULLISH: Trading 165.2% below Wall St target ($18.80)
Trading Range Analysis
30-Day Trading Range
$6.38 -
$7.21
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$6.41
Resistance Level
$7.87
Current Trend
Uptrend
Technical data as of
Jul 6, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.25
Wall Street Target
$18.80
(+165.2%)
Share & Embed Analysis
Last updated: July 06, 2026 11:16 PM ET
Data refreshes hourly during market hours. Next update: 12:16 AM
Data refreshes hourly during market hours. Next update: 12:16 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AURA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Conor Kilroy
SELL
11738 shares
2026-04-16
Amy Elazzouzi
SELL
8549 shares
2026-02-17
Conor Kilroy
SELL
12079 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 64 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 55 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 60 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
